Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  EBV Infection Pré-Inclusion Patients, male or female, aged 12 years and older Patient with fatigue for 1 month or more Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders Patient (and/or parents if necessary) agrees to perform serology for the study Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the study during the pre-inclusion visit Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study Signature of the Informed Consent Form by the patient (and/or parents if necessary) Patient who have a positive serology for EBV (IgG and/or IgM positive)  Patient who have received any treatment with the 2LEBV® or 2LXFS® Patients who have received any homeopathic treatment in the previous 2 months prior to the study Patients under immunosuppressive treatment Patient undergoing treatment for psychiatric disorders Patients having received immunotherapy or micro-immunotherapy during the last 3 months Patients with known lactose intolerance Pregnant or breastfeeding women Patients who participated in a clinical study in the previous 2-months period Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study Patients with severe immunodeficiency disease requiring long term treatment (*) or patients under chemotherapy or radiotherapy